April 22, 2012

A lot has happened across GlaxoSmithKline’s consumer division in the past year. Drug Store News spoke with GSK Consumer chief marketing officer John Graham and chief customer officer Keith Loranger about the next move to be made out of the consumer division’s new playbook.

November 20, 2014

The Generic Pharmaceutical Association on Thursday emphasized the savings generic medicines bring to the table in light of rising brand prices. 

November 20, 2014

Moberg Pharma AB on Thursday announced that Jeff Vernimb has been named general manager for its U.S. operations and a member of Moberg's management team, effective Dec. 15.

 

November 19, 2014

The Food and Drug Administration opened a public docket and requested comments on proposed criteria for “first generic” abbreviated new drug application submissions.

 

November 17, 2014

DSN spoke with Neas in late October to mark the 30th anniversary of the landmark Drug Price Competition and Patent Term Restoration Act — better known as the Hatch-Waxman Act. 

November 17, 2014

Thirty years ago, Democratic and Republican members of Congress hammered out a rare and prescient bipartisan compromise bill that transformed the pharmaceutical landscape forever and unleashed the modern generic drug industry. That law, known as the Hatch-Waxman Act, has proven to be one of the most far-reaching and impactful pieces of legislation ever to shape the American healthcare system.

November 17, 2014

Pharmaceutical sales through HDMA-member traditional primary distributors reached nearly $305 billion in 2013.

November 3, 2014

The RAND Corp. projected that the introduction of biosimilar drugs in the United States will reduce direct spending on biologics by $44.2 billion from 2014 to 2024.

 

October 31, 2014

The response to the current global Ebola scare from both the pharmaceutical and pharmacy industries has been nothing short of remarkable. Precautionary preparations have been made to address the Ebola concerns in the United States; several pharmaceutical manufacturers have been working around the clock toward an Ebola vaccine and treatment; and there has been an outpooring of goods that have been directed to help with the outbreak in West Africa. 

Ebola is not a problem in the United States, at least not yet (nor hopefully will it ever be), but the pharmaceutical community is stepping up to help around the world. And in the U.S., there is much being done to help the pharmacy world prepare.

 

October 24, 2014

In the wake of an Oct. 21 blogpost on Health Affairs, “The $500 Billion Medicare Slowdown: A Story About Part D,” Ralph Neas, president and CEO of the Generic Pharmacuetical Association, issued the following statement.

October 22, 2014

The Food and Drug Administration last week announced plans to survey pharmacists and patients about their experiences resulting from changes in generic drug pill appearance.

October 22, 2014

The pharmaceutical industry has committed considerable resources to developing both vaccines and treatments to address the current Ebola crisis.

 

October 15, 2014

Camber Consumer Care, which focuses on both consumer care and prescription-to-OTC switch products, recently introduced new executives to its staff.

October 15, 2014

The U.S. Supreme Court on Wednesday heard arguments from Teva Pharmaceutical Industries in defense of the patent protecting its $4 billion multiple sclerosis drug Copaxone, according to a Reuters report. 

October 15, 2014

As the Food and Drug Administration begins to explore ways to improve its user-fee program for generic drugs, the Generic Pharmaceutical Association and its members have weighed in with suggestions on how to shore up the law to ensure that it helps bring generics to market faster and provides benefits across the entire healthcare system.

October 15, 2014

What’s in a name? A lot, apparently, if the name applies to a biosimilar medicine.

October 14, 2014

U.S. Sen. Bernie Sanders, I-Vt., and U.S. Rep. Elijah Cummings, D-Md., earlier this month launched an investigation into soaring generic drug prices.

October 14, 2014

Following the completion of a joint venture between GlaxoSmithKline and Novartis' consumer health units, Brian McNamara, currently division head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses.

October 10, 2014

New patient research commissioned by McKesson Patient Relationship Solutions identified emerging trends in medication adherence, the use of co-pay cards, and attitudes towards healthcare providers, including both physicians and pharmacists.

October 8, 2014

Pending legislation in the Pennsylvania state legislature is raising the eyebrows of several industry members, including the National Community Pharmacists Association, which stated that the legislation in its current form would "severely limit access to more affordable medications, vastly increase overall healthcare costs to Pennsylvania businesses and citizens and add cumbersome reporting requirements on healthcare providers."

October 8, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday released a new report highlighting the number of investigational cancer medicines that did not succeed in clinical trials. 

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

October 7, 2014

America’s biopharmaceutical research companies are currently developing nearly 800 new medicines and vaccines for cancer, according to a new PhRMA report.

 

September 29, 2014

According to a report released Monday by Thomson Reuters BioWorld, currently there are 700 follow-on biologics therapies moving through pipelines with many already approved.